Patents by Inventor Jose Medina Echeverz

Jose Medina Echeverz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Combination therapy for treating cancer with an antibody and intravenous administration of a recombinant MVA
    Patent number: 11723964
    Abstract: The invention relates to a pharmaceutical combination and related methods for reducing tumor volume and/or increasing the survival of a cancer patient. The combination comprises an intravenous administration of a recombinant MVA encoding a tumor-associated antigen and an administration of an antibody to a cancer patient.
    Type: Grant
    Filed: March 14, 2022
    Date of Patent: August 15, 2023
    Assignee: Bavarian Nordic A/S
    Inventors: Hubertus Hochrein, Henning Lauterbach, José Medina Echeverz, Matthias Habjan
  • A Recombinant Modified Vaccinia Virus (MVA) Vaccine Against Coronavirus Disease
    Publication number: 20230233670
    Abstract: The invention relates to a recombinant Modified Vaccinia Virus Ankara (MVA) encoding a spike (S) protein or a part thereof, such as a receptor-binding domain (RBD), and additional antigenic sequences derived from other proteins of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the causative agent of coronavirus disease 19 (COVID-19).
    Type: Application
    Filed: June 10, 2021
    Publication date: July 27, 2023
    Applicant: Bavarian Nordic A/S
    Inventors: Jürgen Hausmann, Robin Steigerwald, Matthias Habjan, José Medina Echeverz, Stephan Rambichler
  • Recombinant MVA Viruses for Intratumoral and/or Intravenous Administration for Treating Cancer
    Publication number: 20230190922
    Abstract: The invention relates to a composition and related methods for reducing tumor volume and/or increasing the survival of a cancer patient. The composition comprises a recombinant MVA encoding a Tumor Associated Antigen (“TAA”) as well as 4-1BBL and/or CD40L and can be administered to a subject in any suitable manner, including by intravenous and/or intratumoral administration.
    Type: Application
    Filed: November 20, 2020
    Publication date: June 22, 2023
    Applicant: Bavarian Nordic A/S
    Inventors: Henning Lauterbach, Maria Hinterberger, José Medina Echeverz, Matthias Habjan, Jürgen Hausmann, Markus Kalla
  • Medical Uses of 4-1BBL Adjuvanted Recombinant Modified Vaccinia Virus Ankara (MVA)
    Publication number: 20230059344
    Abstract: The invention relates to a recombinant Modified Vaccinia Virus Ankara (MVA) expressing a TAA and the costimulatory molecule 4-1BBL for use in (i) the prevention of recurrence of a solid tumor, wherein the recombinant MVA is intratumorally administered to the solid tumor, or (ii) the treatment, prevention and/or prevention of recurrence of a tumor, wherein the recombinant MVA is intratumorally administered to another solid tumor.
    Type: Application
    Filed: November 20, 2020
    Publication date: February 23, 2023
    Applicant: Bavarian Nordic A/S
    Inventors: Maria Hinterberger, José Medina Echeverz, Mathias Habjan, Jügen Hausmann, Markus Kalla
  • Combination Therapy for Treating Cancer With an Antibody and Intravenous Administration of a Recombinant MVA
    Publication number: 20220249636
    Abstract: The invention relates to a pharmaceutical combination and related methods for reducing tumor volume and/or increasing the survival of a cancer patient. The combination comprises an intravenous administration of a recombinant MVA encoding a tumor-associated antigen and an administration of an antibody to a cancer patient.
    Type: Application
    Filed: March 14, 2022
    Publication date: August 11, 2022
    Applicant: Bavarian Nordic A/S
    Inventors: Hubertus HOCHREIN, Henning LAUTERBACH, José MEDINA ECHEVERZ, Matthias HABJAN
  • Combination therapy for treating cancer with an intravenous administration of a recombinant MVA and an antibody
    Patent number: 11273211
    Abstract: The invention relates to a pharmaceutical combination and related methods for reducing tumor volume and/or increasing the survival of a cancer patient. The combination comprises an intravenous administration of a recombinant MVA encoding a tumor-associated antigen and an administration of an antibody to a cancer patient.
    Type: Grant
    Filed: August 23, 2018
    Date of Patent: March 15, 2022
    Assignee: Bavarian Nordic A/S
    Inventors: Hubertus Hochrein, Henning Lauterbach, José Medina Echeverz, Matthias Habjan
  • Therapy for Treating Cancer with an Intratumoral or Intravenous Administration of a Recombinant MVA Encoding 4-1BBL (CD137L) and/or CD40L
    Publication number: 20220000997
    Abstract: The invention relates to a composition and related methods for reducing tumor volume and/or increasing the survival of a cancer patient. The composition comprises a recombinant MVA encoding a Tumor Associated Antigen (“TAA”) as well as 4-1BBL and/or CD40L and can be administered to a subject in any suitable manner, including by intravenous and/or intratumoral administration.
    Type: Application
    Filed: November 20, 2019
    Publication date: January 6, 2022
    Applicant: Bavarian Nordic A/S
    Inventors: Henning Lauterbach, Maria Hinterberger, José Medina Echeverz
  • Combination Therapy for Treating Cancer with an Intravenous Administration of a Recombinant MVA and an Antibody
    Publication number: 20200306352
    Abstract: The invention relates to a pharmaceutical combination and related methods for reducing tumor volume and/or increasing the survival of a cancer patient. The combination comprises an intravenous administration of a recombinant MVA encoding a tumor-associated antigen and an administration of an antibody to a cancer patient.
    Type: Application
    Filed: August 23, 2018
    Publication date: October 1, 2020
    Applicant: Bavarian Nordic A/S
    Inventors: Hubertus Hochrein, Henning Lauterbach, José Medina Echeverz, Matthias Habjan
  • Compositions comprising apolipoprotein A polypeptide and interleukin 15, and methods of treatment using the same
    Patent number: 8771664
    Abstract: The present invention relates to compositions capable of promoting both the innate immune response as well as the adaptive immune response in a subject based on the jointly use of ApoA, interleukin 15 and the Sushi domain of the IL15 receptor alpha chain, as well as to the use of these compositions for the stimulation of the immune response in a patient and to therapeutic methods for the treatment of infectious and neoplastic diseases.
    Type: Grant
    Filed: December 10, 2010
    Date of Patent: July 8, 2014
    Assignees: Fundacion para la Investigacion Medica Aplicada, Research Center Borstel
    Inventors: Pedro Berraondo Lopez, Jessica Fioravanti, Jose Medina Echeverz, Ignacio Javier Melero Bermejo, Maria del Carmen Ochoa Nieto, Francisco de Asis Palazon Garcia, Silvia Bulfone-Paus, Erwin Hans Duitmann
  • CONJUGATES AND COMPOSITIONS FOR IMMUNOTHERAPY AND ANTI-TUMORAL TREATMENT
    Publication number: 20120244118
    Abstract: The present invention relates to compositions capable of promoting both the innate immune response as well as the adaptive immune response in a subject based on the jointly use of ApoA, interleukin 15 and the Sushi domain of the IL15 receptor alpha chain, as well as to the use of these compositions for the stimulation of the immune response in a patient and to therapeutic methods for the treatment of infectious and neoplastic diseases.
    Type: Application
    Filed: December 12, 2010
    Publication date: September 27, 2012
    Applicants: FUNDACION PARA LA INVESTIGACION MEDICA APLICADA, RESEARCH CENTER BORSTEL
    Inventors: Pedro Berraondo Lopez, Jessica Fioravanti, Jose Medina Echeverz, Ignacio Javier Melero Bermejo, Maria del Carmen Ochoa Nieto, Francisco de Asis Palazon Garcia, Silvia Bulfone-Paus, Erwin Hans Duitmann